

Ixinity® (coagulation factor IX [recombinant]) – Expanded indication

- On March 26, 2024, <u>Medexus Pharma announced</u> the <u>FDA approval</u> of <u>Ixinity (coagulation factor IX [recombinant])</u>, in adults and children with hemophilia B for:
 - On-demand treatment and control of bleeding episodes
 - Perioperative management
 - Routine prophylaxis to reduce the frequency of bleeding episodes.
- Ixinity was previously approved for these indications in adults and children ≥ 12 years of age. This
 approval expands the label to include pediatric patients < 12 years of age.
- The approval of Ixinity for the expanded indication was based on a study of 21 previously treated
 patients (PTPs) (10 patients < 6 years of age and 11 patients 6 to < 12 years of age). PTP were
 defined as patients who were exposed to a factor IX containing product for 50 exposure days.
 Patients received Ixinity prophylaxis once to twice weekly.
 - The mean total annualized bleeding rate for PTPs < 12 years of age was 2.34 (standard deviation ± 4.23).
 - There were 52 bleeding episodes; nine did not require treatment and resolved with Ixinity routine prophylaxis once or twice-weekly treatment. In 45 of 52 (86.5%) of the episodes, hemostasis was achieved with zero to two infusions. For four bleeding episodes (7.7%) three infusions were required, two episodes (3.8%) four infusions were required, and one episode (1.9%) required five infusions for resolution.
- Ixinity is administered via intravenous infusion. Refer to the Ixinity drug label for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.